1:30 Learning hours


Active surveillance for localised prostate cancer

A review of the current evidence, NICE 2019 guideline and tools to help you and your patients.

Accredited by the Royal College of Surgeons of England for up to 2.0 CPD points.

Following completion of this module, you should:

  • Know the current status of active surveillance in the UK, including patient and physician attitudes.
  • Understand the 2019 updates to the NICE guideline on the diagnosis and management of prostate cancer, particularly those relating to active surveillance.
  • Have an understanding of the Prostate Cancer UK clinical consensus statement, which, along with the NICE guideline, sets out the best practice for offering active surveillance using multi-parametric magnetic resonance imaging (mpMRI) scans.
  • Be familiar with the key tools that are available to help you discuss active surveillance with your patients and support them in making the best decisions about their care.
  • Know how patients with anxieties about active surveillance might be supported (using the consultant and patient films from Prostate Cancer UK).

NICE, National Institute for Health and Care Excellence.